We encountered a patient with symptomatic regrowth of paraaortic lymph node metastasis from prostatic cancer. He had previously received 58.4 Gy of radiotherapy to the same region 12 months prior. Brachytherapy needles and a HGI needle were deployed via the paravertebral approach under local anesthesia at our outpatient clinic.
A single dose of 22.5 Gy (equivalent to 60.94 Gy in 2 Gy per fraction schedule calculated at ¦Á/¦Â = 10) was delivered to the target, with preservation of the surrounding small intestine by HGI with D2cc (minimum dose to the most irradiated volume of 2 mL) of 5.05 Gy. Therapeutic ratio was 3.64 times higher for this brachytherapy plan compared with an intensity-modulated radiation therapy plan. At followup at 1 year after brachytherapy, the symptoms had disappeared, tumor size had reduced with no fluorodeoxyglucose accumulation, and prostate-specific antigen level had decreased.
We consider that high-dose-rate brachytherapy with the HGI procedure offers effective treatment even in this type of reirradiation situation.